Business Standard

Biosimilar market on the growth path as top drugs double in size

Data shows while the overall biosimilars category has clocked a 10.3% value compound annual growth rate (CAGR) over the past few years, the market size for the top molecule has more than doubled

medicine, pharma
Premium

Sohini Das Mumbai
As the domestic market wakes up to a wider use of biologic drugs and as patient compliance improves, the biosimilars segment is seeing a higher growth of late. 

Data shows while the overall biosimilars category has clocked a 10.3 per cent value compound annual growth rate (CAGR) over the past few years, the market size for the top molecule has more than doubled. 

A biologic drug is produced from living organisms or contains components of living organisms, unlike chemical drugs. A biosimilar is a copy-cat of a biologic drug, once the patent period ends. The moving annual turover (MAT) for biosimilar molecules

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 26 2019 | 8:54 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com